Budigalimab, an anti-PD-1 inhibitor, for people living with HIV-1: a randomized, placebo-controlled phase 1b study
- DOI
- 10.1038/s41591-025-03993-0
- Published
- 2025-10-15
- Container
- Nature Medicine
- Publisher
- Springer Science and Business Media LLC
- Open access
- unknown
Credibility signals
uncertain Score 64/100 under policy 1.0.0. This is a metadata assessment, not a judgment of the paper's conclusions.
Show all credibility signals
- supportingDOI registered: A matching record was returned by Crossref.
- supportingDOI resolves: A matching record was returned by Crossref.
- not scoredDirectory of Open Access Journals: No matching DOAJ record was present in this response. No allow-list match; this is not evidence of low credibility.
- not scoredMEDLINE indexed: Not checked or no result supplied; no credibility inference made.
- not scoredOpenAlex core source: Not checked or no result supplied; no credibility inference made.
- not scoredKnown publisher allow-list: Not checked or no result supplied; no credibility inference made.
- not scoredROR affiliation: Not checked or no result supplied; no credibility inference made.
- not scoredRetraction Watch retraction: No retraction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- not scoredRetraction Watch expression of concern: No expression of concern notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- not scoredRetraction Watch correction: No correction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- not scoredRetraction Watch reinstatement: No reinstatement notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- not scoredOpen access status: Not checked or no result supplied; no credibility inference made.
- not scoredPublication license: Not checked or no result supplied; no credibility inference made.
- not scoredPublication version: A publication version was supplied but is not scored.
- supportingMetadata completeness: All 6 scored descriptive metadata groups are present.
Cite this work
BibTeX
@article{allodium:10.1038/s41591-025-03993-0,
title = {Budigalimab, an anti-PD-1 inhibitor, for people living with HIV-1: a randomized, placebo-controlled phase 1b study},
author = {Moti N. Ramgopal and Jacob P. Lalezari and Ana Gabriela Pires dos Santos and Preethi Krishnan and Tanaya R. Vaidya and Fei Zhou and Heide Betman and Patrick Dorr and Nael M. Mostafa and Maria L. Alcaide and Franco Felizarta and Jean-Pierre Routy},
year = {2025},
journal = {Nature Medicine},
doi = {10.1038/s41591-025-03993-0},
url = {https://doi.org/10.1038/s41591-025-03993-0}
}RIS
TY - JOUR TI - Budigalimab, an anti-PD-1 inhibitor, for people living with HIV-1: a randomized, placebo-controlled phase 1b study AU - Moti N. Ramgopal AU - Jacob P. Lalezari AU - Ana Gabriela Pires dos Santos AU - Preethi Krishnan AU - Tanaya R. Vaidya AU - Fei Zhou AU - Heide Betman AU - Patrick Dorr AU - Nael M. Mostafa AU - Maria L. Alcaide AU - Franco Felizarta AU - Jean-Pierre Routy PY - 2025 JO - Nature Medicine DO - 10.1038/s41591-025-03993-0 UR - https://doi.org/10.1038/s41591-025-03993-0 ER -
APA
Ramgopal, M. N., Lalezari, J. P., Santos, A. G. P. D., Krishnan, P., Vaidya, T. R., Zhou, F., Betman, H., Dorr, P., Mostafa, N. M., Alcaide, M. L., Felizarta, F., & Routy, J. (2025). Budigalimab, an anti-PD-1 inhibitor, for people living with HIV-1: a randomized, placebo-controlled phase 1b study. Nature Medicine. https://doi.org/10.1038/s41591-025-03993-0
Source records
- crossref · retrieved 2026-09-25T20:06:52.076Z